Charles Swanton
#62,215
Most Influential Person Now
Senior Group Leader at the Francis Crick Institute
Why Is Charles Swanton Influential?
(Suggest an Edit or Addition)According to Wikipedia, Charles Swanton is British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, Royal Society Napier Professor in Cancer and thoracic medical oncologist at University College London and University College London Hospitals, co-director of the Cancer Research UK Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.
Charles Swanton's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. (2012) (5741)
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (2016) (2221)
- The causes and consequences of genetic heterogeneity in cancer evolution (2013) (1850)
- Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future (2017) (1653)
- Tracking the Evolution of Non‐Small‐Cell Lung Cancer (2017) (1525)
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018) (1327)
- Phylogenetic ctDNA analysis depicts early stage lung cancer evolution (2017) (1092)
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing (2014) (1080)
- Renal cell carcinoma (2017) (1023)
- Spatial and temporal diversity in genomic instability processes defines lung cancer evolution (2014) (934)
- Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. (2015) (857)
- Intratumor heterogeneity: evolution through space and time. (2012) (814)
- deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution (2016) (801)
- Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution (2017) (772)
- Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution (2017) (772)
- Chromosomal instability drives metastasis through a cytosolic DNA response (2017) (766)
- Cancer heterogeneity: implications for targeted therapeutics (2013) (749)
- Preexisting and de novo humoral immunity to SARS-CoV-2 in humans (2020) (720)
- Replication stress links structural and numerical cancer chromosomal instability (2013) (697)
- Artificial intelligence in cancer imaging: Clinical challenges and applications (2019) (689)
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer (2018) (688)
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. (2017) (597)
- Toward understanding and exploiting tumor heterogeneity (2015) (557)
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution (2015) (550)
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA (2020) (517)
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal (2018) (514)
- Neoantigen-directed immune escape in lung cancer evolution (2019) (504)
- Intratumor Heterogeneity: Seeing the Wood for the Trees (2012) (486)
- Metastasis as an evolutionary process (2016) (444)
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination (2021) (414)
- How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine (2010) (403)
- Chromosomal instability confers intrinsic multidrug resistance. (2011) (400)
- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal (2018) (391)
- Genetic prognostic and predictive markers in colorectal cancer (2009) (384)
- Translational Implications of Tumor Heterogeneity (2015) (383)
- Clinical management of breast cancer heterogeneity (2015) (382)
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies (2018) (376)
- Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. (2007) (368)
- Tumour heterogeneity and the evolution of polyclonal drug resistance (2014) (364)
- Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins (1997) (358)
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers (2017) (357)
- COVID-19: the case for health-care worker screening to prevent hospital transmission (2020) (356)
- Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic (2020) (349)
- Resolving genetic heterogeneity in cancer (2019) (349)
- APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. (2015) (346)
- Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal (2018) (333)
- Genetic prognostic and predictive markers in colorectal cancer (2011) (333)
- Cancer chromosomal instability: therapeutic and diagnostic challenges (2012) (327)
- Origins of lymphatic and distant metastases in human colorectal cancer (2017) (319)
- Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. (2014) (310)
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition (2021) (306)
- Paradoxical relationship between chromosomal instability and survival outcome in cancer. (2011) (302)
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. (2018) (297)
- Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study (2020) (296)
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2018) (296)
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (292)
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (292)
- Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers (2019) (287)
- Classifying the evolutionary and ecological features of neoplasms (2017) (276)
- Chromosomal instability determines taxane response (2009) (256)
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. (2019) (253)
- Cell-cycle targeted therapies. (2004) (243)
- Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma (2017) (238)
- Determinants and clinical implications of chromosomal instability in cancer (2018) (234)
- Anthracycline cardiotoxicity (2006) (231)
- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (231)
- Clinical Implications of Genomic Discoveries in Lung Cancer. (2016) (230)
- Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection (2018) (230)
- Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes (2016) (223)
- Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. (2015) (213)
- UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma (2019) (209)
- Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study (2014) (208)
- The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel (2007) (207)
- Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers (2020) (202)
- Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers (2020) (202)
- Scientific consensus on the COVID-19 pandemic: we need to act now (2020) (185)
- Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine (2014) (182)
- Cancer: evolution within a lifetime. (2014) (178)
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. (2021) (176)
- Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery (2010) (167)
- The Role of Aneuploidy in Cancer Evolution. (2017) (166)
- Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes (2020) (166)
- Pervasive chromosomal instability and karyotype order in tumour evolution (2020) (160)
- The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome (2017) (150)
- Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer (2011) (144)
- Modulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma‐associated herpesvirus (1999) (142)
- Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (141)
- Tumor Evolution as a Therapeutic Target. (2017) (141)
- Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (141)
- SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair (2015) (140)
- Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers (2014) (140)
- Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions (2019) (137)
- Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. (2016) (136)
- Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab (2006) (135)
- Prioritizing targets for precision cancer medicine. (2014) (135)
- A comprehensive survey of the mutagenic impact of common cancer cytotoxics (2016) (130)
- Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease (2016) (129)
- Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. (2013) (124)
- DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer (2016) (124)
- Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2019) (119)
- The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis (2019) (119)
- Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2019) (119)
- Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. (2010) (115)
- Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. (2015) (112)
- Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy (2009) (111)
- Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2019) (110)
- Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution (2018) (110)
- Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2019) (110)
- Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (109)
- Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (109)
- The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE” (2016) (104)
- Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections (2020) (102)
- Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target (2012) (101)
- Spatial heterogeneity in medulloblastoma (2017) (101)
- 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients (2014) (101)
- The function and dysfunction of memory CD8+ T cells in tumor immunity (2018) (100)
- The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. (2018) (99)
- Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution (2015) (99)
- Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study (2021) (97)
- Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas (2013) (97)
- AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC (2021) (95)
- A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors (2013) (95)
- Parallel evolution of tumour subclones mimics diversity between tumours (2013) (93)
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (2021) (91)
- The centriolar satellite protein Cep131 is important for genome stability (2012) (85)
- Kidney cancer: The next decade (2018) (84)
- Neoantigen quality, not quantity (2019) (82)
- Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions (2016) (80)
- APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability. (2017) (80)
- Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses (2020) (79)
- BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer (2017) (79)
- Chromosomal Instability, Colorectal Cancer and Taxane Resistance (2006) (79)
- Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. (1999) (78)
- Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. (2010) (76)
- The National Lung Matrix Trial of personalized therapy in lung cancer (2020) (76)
- Consensus on precision medicine for metastatic cancers: a report from the MAP conference. (2016) (75)
- Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma (2017) (71)
- Her2-Targeted Therapies in Non–Small Cell Lung Cancer (2006) (70)
- Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma (2021) (68)
- Molecular classification of solid tumours: towards pathway-driven therapeutics (2009) (67)
- Metastasis and immune evasion from extracellular cGAMP hydrolysis. (2020) (67)
- The evolution of the unstable cancer genome. (2014) (67)
- Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients (2021) (65)
- A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers (2012) (65)
- Optimizing panel-based tumor mutational burden (TMB) measurement. (2019) (65)
- SnapShot: Renal Cell Carcinoma (2015) (65)
- Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. (2016) (64)
- Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution (2014) (62)
- Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. (2015) (61)
- The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer (2015) (61)
- AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity (2021) (60)
- The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. (2017) (60)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- A clonal expression biomarker associates with lung cancer mortality (2019) (59)
- Cancer Evolution Constrained by the Immune Microenvironment (2017) (59)
- The T cell differentiation landscape is shaped by tumour mutations in lung cancer (2020) (59)
- The T cell differentiation landscape is shaped by tumour mutations in lung cancer (2020) (59)
- Consequences of COVID-19 for cancer care — a CRUK perspective (2020) (58)
- Three-dose vaccination elicits neutralising antibodies against omicron (2022) (57)
- Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts. (2019) (57)
- Implications of intratumour heterogeneity for treatment stratification (2014) (57)
- Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study (2019) (57)
- Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. (2014) (55)
- Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics. (2012) (55)
- Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling (2017) (54)
- Genomic instability in mutant p53 cancer cells upon entotic engulfment (2018) (54)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment (2021) (53)
- Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. (2017) (53)
- Breast cancer genome heterogeneity: a challenge to personalised medicine? (2011) (52)
- CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid‐specific cancer cell death through autophagy induction (2012) (52)
- Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 (2021) (52)
- Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 (2021) (52)
- Modelling the evolution of genetic instability during tumour progression (2012) (52)
- Inferring mutational timing and reconstructing tumour evolutionary histories. (2015) (52)
- Epigenetic regulation in RCC: opportunities for therapeutic intervention? (2012) (51)
- Cancer evolution: Darwin and beyond (2021) (51)
- Targeting chromosomal instability and tumour heterogeneity in HER2‐positive breast cancer (2010) (51)
- Escape from nonsense-mediated decay associates with anti-tumor immunogenicity (2019) (51)
- Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. (2011) (49)
- Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. (2012) (48)
- HELQ promotes RAD51 paralog-dependent repair to avert germ cell attrition and tumourigenesis (2013) (48)
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC). (2019) (48)
- Extrachromosomal DNA - relieving heredity constraints, accelerating tumour evolution. (2020) (47)
- New approaches for improving outcomes in breast cancer in Europe. (2015) (47)
- 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy (2021) (46)
- Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters (2017) (46)
- Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. (2017) (46)
- Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer (2022) (46)
- SARS-CoV-2 virus and antibodies in front-line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study (2020) (45)
- Immune surveillance in clinical regression of pre-invasive squamous cell lung cancer (2019) (45)
- Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications (2013) (44)
- Optimizing panel-based tumor mutational burden (TMB) measurement. (2019) (44)
- Genetic contribution of three introduced life history forms of sockeye salmon to colonization of Frazer Lake, Alaska (2000) (44)
- Collateral damage: the impact on cancer outcomes of the COVID-19pandemic (2020) (44)
- Adapting clinical paradigms to the challenges of cancer clonal evolution. (2013) (44)
- Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets (2010) (44)
- Tracking Cancer Evolution through the Disease Course. (2021) (43)
- TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen (2015) (42)
- LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development (2013) (40)
- FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. (2009) (39)
- Re-Evaluating Clonal Dominance in Cancer Evolution. (2016) (39)
- Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses. (2019) (38)
- Tumour heterogeneity and immune-modulation (2013) (38)
- Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. (2020) (37)
- Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. (2017) (37)
- Taxane benefit in breast cancer—a role for grade and chromosomal stability (2013) (37)
- Ccdc13 is a novel human centriolar satellite protein required for ciliogenesis and genome stability (2014) (37)
- Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. (2018) (36)
- Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains (2021) (36)
- Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts (2021) (36)
- Genomic landscape of platinum resistant and sensitive testicular cancers (2020) (35)
- Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome (2015) (35)
- The centriolar satellite protein Cep131 is important for genome stability (2013) (35)
- Can oncology recapitulate paleontology? Lessons from species extinctions (2015) (35)
- Selection of metastasis competent subclones in the tumour interior (2020) (35)
- Analysis of intratumor heterogeneity unravels lung cancer evolution (2015) (34)
- Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis (2017) (34)
- RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress (2015) (34)
- Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
- Cancer evolution: the final frontier of precision medicine? (2014) (33)
- How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma? (2015) (33)
- Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer (2021) (32)
- A Simple Stratified Design for Mark-Recapture Estimation of Salmon Smolt Abundance (1998) (32)
- Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. (2021) (32)
- Intratumor heterogeneity reflects clinical disease course (2020) (32)
- Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer. (2011) (32)
- Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 (2016) (31)
- Cyclin D mediates tolerance of genome-doubling in cancers with functional p53 (2016) (31)
- Molecular profiling and the reclassification of cancer: divide and conquer. (2013) (31)
- The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer (2013) (31)
- Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? (2012) (30)
- My Cancer Genome: a unified genomics and clinical trial portal (2012) (30)
- Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. (2016) (30)
- Minimising Immunohistochemical False Negative ER Classification Using a Complementary 23 Gene Expression Signature of ER Status (2010) (30)
- Erratum: Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions (2017) (30)
- Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment (2018) (29)
- Abstract CT023: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study (2020) (29)
- Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges. (2013) (29)
- Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution (2017) (29)
- The Genome of the Chicken DT40 Bursal Lymphoma Cell Line (2014) (28)
- Overcoming inhibitions: subversion of CKI function by viral cyclins. (1999) (28)
- Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies. (2010) (28)
- Spatial and temporal cancer evolution: causes and consequences of tumour diversity. (2014) (27)
- Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine (2016) (27)
- Implications of cancer evolution for drug development (2017) (27)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (27)
- Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma? (2012) (26)
- Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. (2021) (26)
- Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study. (2018) (26)
- Constraints in cancer evolution. (2017) (26)
- Acquired resistance to crizotinib from a mutation in CD74-ROS1. (2013) (26)
- Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity (2011) (25)
- Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients (2022) (25)
- Chromosomal Instability, Aneuploidy, and Cancer (2014) (25)
- SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies (2022) (24)
- MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically (2020) (24)
- Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion (2021) (24)
- P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery (2021) (23)
- Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry (2021) (23)
- Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. (2012) (23)
- Cancer evolution constrained by mutation order. (2015) (22)
- Computational optimisation of targeted DNA sequencing for cancer detection (2013) (22)
- Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer (2008) (22)
- Targeting polo-like kinase: learning too little too late? (2008) (22)
- Epothilones and new analogues of the microtubule modulators in taxane-resistant disease (2008) (22)
- Prospective analysis of 895 patients on a UK Genomics Review Board (2019) (21)
- Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories (2020) (21)
- Cancer Research: The lessons to learn from COVID-19. (2020) (21)
- Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study (2021) (20)
- Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution (2017) (20)
- Percutaneous endoscopic gastrostomy at the time of tumour resection in advanced oral cancer. (2000) (20)
- Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer (2021) (20)
- Evolving adoptive cellular therapies in urological malignancies. (2017) (20)
- Using DNA sequencing data to quantify T cell fraction and therapy response (2021) (19)
- Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study (2021) (19)
- TRACERx Renal: tracking renal cancer evolution through therapy (2017) (19)
- A functional taxonomy of tumor suppression in oncogenic KRAS-driven lung cancer. (2021) (19)
- Deconvolving Convolutional Neural Network for Cell Detection (2018) (19)
- Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis (2020) (18)
- Handbook of Metastatic Breast Cancer (2006) (18)
- Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway. (2017) (18)
- From genomic landscapes to personalized cancer management—is there a roadmap? (2010) (18)
- Unintended on-target chromosomal instability following CRISPR/Cas9 single gene targeting (2020) (18)
- 93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy (2021) (18)
- Epothilones and new analogues of the microtubule modulators in taxane-resistant disease. (2008) (17)
- Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study (2021) (17)
- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (17)
- A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors. (2011) (17)
- Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action (2011) (16)
- International cancer seminars: a focus on kidney cancer. (2016) (16)
- Unraveling the complexity of endocrine resistance in breast cancer by functional genomics. (2008) (16)
- Impact of cancer evolution on immune surveillance and checkpoint inhibitor response (2021) (16)
- The Value of Patient and Public Involvement in Trial Design and Development. (2015) (16)
- Initiation of High Frequency Multi-Drug Resistance Following Kinase Targeting by siRNAs (2007) (16)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay. (2021) (16)
- Scalable and robust SARS-CoV-2 testing in an academic center (2020) (15)
- Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. (2021) (15)
- Evaluation of cell-free DNA approaches for multi-cancer early detection. (2022) (15)
- Recent Developments in Treatment Stratification for Metastatic Breast Cancer (2011) (15)
- Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. (2014) (15)
- Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data (2014) (15)
- Scalable and robust SARS-CoV-2 testing in an academic center (2020) (15)
- The translational challenges of precision oncology. (2022) (14)
- Quantification of tumour evolution and heterogeneity via Bayesian epiallele detection (2017) (14)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay (2020) (14)
- A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer (2022) (14)
- RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress (2016) (14)
- Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression (2022) (13)
- An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood. (2018) (13)
- Take lessons from cancer evolution to the clinic (2020) (13)
- Melanoma dedifferentiation induced by IFN- γ epigenetic remodeling in response to anti–PD-1 therapy (2021) (13)
- IFN-gamma down-regulates MHC expression and antigen processing in a human B cell line. (1999) (13)
- WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed (2022) (13)
- A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit (2010) (13)
- The evolutionary dynamics of extrachromosomal DNA in human cancers (2022) (13)
- Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. (2016) (13)
- Principles of ecDNA random inheritance drive rapid genome change and therapy resistance in human cancers (2021) (12)
- Expansion of airway basal epithelial cells from primary human non‐small cell lung cancer tumors (2018) (12)
- Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer (2014) (11)
- Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. (2016) (11)
- Epigenetic noise fuels cancer evolution. (2014) (11)
- Capturing cancer evolution using genetically engineered mouse models (GEMMs). (2021) (11)
- Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy (2020) (11)
- Securing the future of the clinician-scientist (2020) (11)
- Evidence That STK19 Is Not an NRAS-dependent Melanoma Driver (2020) (11)
- MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution (2021) (11)
- Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance (2020) (11)
- RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy? (2004) (10)
- 1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study (2021) (10)
- An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations. (2022) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Environmental emissions, public health and lung cancer risk. (2016) (10)
- Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer (2018) (10)
- The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released. (2017) (10)
- A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables (2011) (10)
- Cancer chromosomal instability : therapeutic and diagnostic challenges ‘ Exploring aneuploidy : the significance of chromosomal imbalance ’ review series (2012) (10)
- Promoting predictive, preventive and personalised medicine: European event of global importance (2011) (9)
- MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. (2021) (9)
- Cancer therapeutics through an evolutionary lens (2018) (9)
- Plasma-derived tumor DNA analysis at whole-genome resolution. (2013) (9)
- 1928O Meta-analysis of tumour and T cell intrinsic mechanisms of sensitization to checkpoint inhibition (2020) (9)
- MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents. (2015) (9)
- Immunity Report Fc-Optimized Anti-CD 25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (8)
- Cellular Prion Protein PrPC and Ecto-5'-Nucleotidase Are Markers of the Cellular Stress Response to Aneuploidy. (2017) (8)
- Evolutionary Precision Medicine: A Role for Repeat Epidermal Growth Factor Receptor Analysis in ALK-Rearranged Lung Adenocarcinoma? (2015) (8)
- Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy. (2021) (8)
- A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms (2021) (8)
- Evolutionary dynamics in pre-invasive neoplasia. (2017) (8)
- Cancer Screening, Surrogates of Survival, and the Soma. (2020) (8)
- Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy. (2016) (8)
- A Genomic-Profile Derived Summary Measure of Chromosomal Breakpoints Predicts Response to Treatment with the DNA-Damaging Agent Cisplatin. (2009) (8)
- The evolution of lung cancer and impact of subclonal selection in TRACERx (2023) (7)
- A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories (2013) (7)
- Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer (2022) (7)
- RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance (2009) (7)
- Cell-Free DNA–Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial (2022) (7)
- SAFIR01: steps towards precision treatment in breast cancer. (2014) (7)
- Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies. (2011) (7)
- Intratumor Heterogeneity and Branched Evolution REPLY (2012) (7)
- Whole Genome Doubling mitigates Muller’s Ratchet in Cancer Evolution (2019) (7)
- Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial (2013) (7)
- Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study (2019) (6)
- Tetraploidy and CIN: a dangerous combination (2015) (6)
- Gastrointestinal cancer: Tracking tumour evolution through liquid biopsy (2015) (6)
- ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma. (2016) (6)
- The evolution of non-small cell lung cancer metastases in TRACERx (2023) (6)
- Genomic–transcriptomic evolution in lung cancer and metastasis (2023) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for Annals of Oncology. (2014) (6)
- Clinical outcomes of SARS-CoV-2 pandemic in long-term care facilities for people with epilepsy: observational study (2020) (6)
- Genomic–transcriptomic evolution in lung cancer and metastasis (2023) (6)
- Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE" (2017) (6)
- Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway. (2017) (6)
- Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC). (2012) (5)
- APOBEC3B expression generates an immunogenic model of Kras mutant lung cancer (2020) (5)
- Protecting “covid protected” cancer hubs (2020) (5)
- Abstract OT1-1-14: Open-label, Phase II trial of afatinib, with or without vinorelbine, for the treatment of HER2-overexpressing inflammatory breast cancer (IBC)* (2012) (5)
- Prognostic and predictive markers in metastatic renal cell carcinoma. (2013) (5)
- A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer. (2011) (5)
- RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma (2022) (5)
- KRAS 3'-UTR variants and stratification of breast-cancer risk. (2011) (5)
- Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. (2017) (5)
- ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors (2021) (5)
- CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia (2022) (4)
- Abstract LB-A03: Allele specific HLA loss and immune escape in lung cancer evolution (2018) (4)
- Meta-analysis of tumor and T cell intrinsic mechanisms of sensitization to checkpoint inhibition (2020) (4)
- Re-Evaluating Clonal Dominance in Cancer (2016) (4)
- Combined inhibition of BRAF and MEK in melanoma patients. (2014) (4)
- Response to W.C. Taylor, and C. Fiala and E.P. Diamandis. (2020) (4)
- Abstract LB-343: Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA) (2018) (4)
- Characterisation of tumour immune microenvironment remodelling following oncogene inhibition in preclinical studies using an optimised imaging mass cytometry workflow (2021) (4)
- Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma (2021) (4)
- Review: Systemic therapy for advanced renal cell carcinoma (2009) (4)
- Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure (2008) (4)
- Comprar Handbook Of Metastatic Breast Cancer 2nd Ed. | Stephen Johnston | 9781841848112 | Informa Healthcare (2011) (4)
- Emergence of new subgenomic mRNAs in SARS-CoV-2 (2022) (4)
- Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA (2023) (4)
- NHS-Galleri Trial Design: Equitable study recruitment tactics for targeted population-level screening with a multi-cancer early detection (MCED) test. (2022) (4)
- Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer (2022) (3)
- Defining the lethal subclone in metastatic lung cancer. (2018) (3)
- Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (3)
- Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers (2017) (3)
- Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (3)
- Understanding the impact of immune-mediated selection on lung cancer evolution (2021) (3)
- Author Correction: Resolving genetic heterogeneity in cancer (2019) (3)
- cloneMap: a R package to visualise clonal heterogeneity (2022) (3)
- ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma (2019) (3)
- Lung adenocarcinoma promotion by air pollutants (2023) (3)
- Advances in personalised therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity (2009) (3)
- Cancer evolution: the final frontier of precision medicine? (2014) (3)
- Antibodies against endogenous retroviruses promote lung cancer immunotherapy (2023) (3)
- Abstract 964: Intra-tumor heterogeneity and Darwinian selection revealed by multi-region exome sequencing of renal cell carcinomas (2012) (3)
- Evolution and cancer medicine — transformative insights (2017) (3)
- Response to Bakhoum et al. (2014) (3)
- Relapse models for clear cell renal carcinoma. (2015) (3)
- Multidisciplinary urological engagement in translational renal cancer research (2014) (3)
- Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer (2012) (3)
- Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (2)
- Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges (2022) (2)
- Early immune pressure imposed by tissue resident memory T cells sculpts tumour evolution in non-small cell lung cancer (2021) (2)
- Non-Small-Cell Lung Cancer Promotion by Air Pollutants (2022) (2)
- Cyclin D mediates tolerance of genome-doubling in cancers with functional p53. (2016) (2)
- Effect of delays in the UK two-week wait cancer referral pathway during the COVID-19 pandemic on cancer survival: a modelling study (2020) (2)
- Breast cancer in the post-genomic era (2010) (2)
- The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care (2023) (2)
- E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion (2021) (2)
- Intratumor heterogeneity in non-small cell lung cancer inferred by multi-region exome sequencing (2014) (2)
- The proteasome regulator PSME4 drives immune evasion and abrogates anti-tumor immunity in NSCLC (2021) (2)
- 655 Preliminary report of efficacy of abiraterone acetate in patients with estrogen (ER) or androgen receptor (AR) positive, advanced breast carcinoma resistant to standard endocrine therapies (2010) (2)
- Abstract NG03: Chromosomal instability promotes metastasis through a cytosolic DNA response (2018) (2)
- Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities. (2022) (2)
- 217 Identifying the metastatic subclone by exhaustive sampling of primary and metastasis in clear cell renal cell carcinoma (ccRCC) pair (2016) (2)
- Exploiting interleukin 6 in multicentric Castleman's disease (2014) (2)
- defines lung cancer evolution Spatial and temporal diversity in genomic instability processes (2014) (2)
- IFN-γ Down-Regulates MHC Expression and Antigen Processing in a Human B Cell Line (1999) (2)
- Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay (2022) (2)
- Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay (2022) (2)
- Parallel evolution of tumor subclones mimics diversity between tumors (2013) (2)
- Copy number-aware deconvolution of tumor-normal DNA methylation profiles (2020) (2)
- Determinants of anti-PD1 response and resistance in clear cell renal cell carcinoma (2021) (2)
- Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment (2021) (2)
- Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (2)
- Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications (2013) (1)
- Cytokine release syndrome in a patient with colorectal cancer following vaccination with BNT162b2 (tozinameran) (2021) (1)
- An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations (2022) (1)
- Cisplatin is more mutagenic than carboplatin or oxaliplatin at equitoxic concentrations (2020) (1)
- Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling (2017) (1)
- Author Correction: The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis (2020) (1)
- Biomarker Profiles in Trastuzumab (T) Refractory HER2+ Inflammatory Breast Cancer (IBC) That Predict for Survival Benefit from Lapatinib (L) Monotherapy. (2009) (1)
- AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
- 3MO Genomic evolution of non-small cell lung cancer during the establishment and propagation of patient-derived xenograft models (2022) (1)
- Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity. (2021) (1)
- 571 A focused, PCR based gene expression signature to refine grade in breast cancer (2010) (1)
- Genomic evolution of non-small cell lung cancer patient-derived xenograft models (2023) (1)
- Immunogenomic profile of colorectal cancer response to immune checkpoint blockade (2020) (1)
- 880PBiomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium) (2017) (1)
- Abstract 5249: Intratumor heterogeneity and the detection of potential driver mutations in cfDNA in a NSCLC cohort using UltraSEEKTM (2015) (1)
- Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions (2019) (1)
- Broad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccination (2021) (1)
- Erratum: Genetic prognostic and predictive markers in colorectal cancer (Nature Reviews Cancer (2009) 9 (489-499)) (2011) (1)
- A Functional Role for CERT in Cancer Drug Induced Autophagy and Prognosis in Her2 Positive Breast Cancer. (2009) (1)
- 31 Genomic and Mutational Profiling of Tumours to Facilitate Personalised Medicine (2012) (1)
- Parallel selection of chemotherapy-resistant cell lines to illuminate mechanisms of drug resistance in human tumors: Abstract of paper from the IMPAKT Breast Cancer Conference (2011) (1)
- RBTT-06. TESSA JOWELL BRAIN MATRIX STUDY: A BRITISH FEASIBILITY STUDY OF MOLECULAR STRATIFICATION AND TARGETED THERAPY TO OPTIMIZE THE CLINICAL MANAGEMENT OF PATIENTS WITH GLIOMA (2019) (1)
- Academically led clinical trials: challenges and opportunities (2015) (1)
- Characterisation of the TCR repertoire in NSCLC to reveal the relationship between TCR heterogeneity and genetic heterogeneity that is influenced by mutational load and is associated with disease recurrence. (2018) (1)
- Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data (2014) (1)
- P3.03-005 Inhibition of PRMT5 is Synthetic Lethal in Mesotheliomas Harboring MTAP Loss: Topic: Mesothelioma Transitional (2017) (1)
- Modulation of p 27 Kip 1 levels by the cyclin encoded by Kaposi ’ s sarcoma-associated herpesvirus (2013) (1)
- Regulators of Mitotic Transition Determine Paclitaxel Resistance In Vitro and Predict Poor Prognosis in Breast Cancer In Vivo. (2009) (1)
- A-PREDICT: A phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy (CRUKE/11/061). (2014) (1)
- Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort (2021) (1)
- Spatial patterns of tumour growth impact clonal diversification: computational modelling and evidence in the TRACERx Renal study (2021) (1)
- 1 The Role of Aneuploidy in Cancer Evolution (2018) (1)
- Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? (2012) (1)
- Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity (2011) (1)
- Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancer (2020) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Abstract 5601: Single-cell molecular profiling of circulating tumor cells (CTCs) within the TRACERx study reveals heterogeneous patterns in early non-small cell lung cancer (NSCLC) (2018) (1)
- PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC) (2019) (1)
- Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer (2020) (1)
- Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II). (2017) (1)
- OT3-01-16: A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER+) Breast Cancer. (2011) (1)
- Misuse of SARS-CoV-2 testing in symptomatic health-care staff in the UK – Authors' reply (2020) (1)
- Northeast and Midwest regional species and habitats at greatest risk and most vulnerable to climate impacts (2016) (1)
- Evolutionary characterisation of lung adenocarcinoma morphology in TRACERx (2023) (1)
- Author Correction: Scalable and robust SARS-CoV-2 testing in an academic center (2020) (1)
- Author Correction: Scalable and robust SARS-CoV-2 testing in an academic center (2020) (1)
- Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways. (2023) (1)
- Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma (2023) (1)
- TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen (2015) (1)
- Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes (2023) (1)
- 1123O Evaluation of cell-free DNA approaches for multi-cancer early detection (2021) (1)
- Stock interrelationships of sockeye salmon runs, Alitak Bay District, Kodiak Island, Alaska (1992) (1)
- Abstract 5818: Features of cancer cachexia in non-small cell lung cancer: Insights from the prospective TRACERx study (2022) (0)
- 879PUrine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC) (2017) (0)
- Abstract 3096: Multi-region patient-derived xenograft models from non-small cell lung cancer patients enrolled in lung TRACERx (2022) (0)
- Genomic landscape of platinum resistant and sensitive testicular cancers (2020) (0)
- Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage. (2019) (0)
- Understanding Complex Tumor Heterogeneity (2013) (0)
- Principles of Targeted and Biological Therapies (2006) (0)
- 134PCirculating tumour DNA (ctDNA) in the clinical management of patients (pts) with advanced non-small cell lung cancer (NSCLC): A single centre experience (2017) (0)
- 104ININTRAPATIENT HETEROGENEITY AND CLONAL EVOLUTION: WHAT PRECISION MEDICINE? (2014) (0)
- Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study (2021) (0)
- Abstract 3123: Lung cancer evolutionary trajectories in PEACE (2021) (0)
- Genomic instability in mutant p53 cancer cells upon entotic engulfment (2018) (0)
- Planetary science: Venusian hot flow anomalies (2012) (0)
- Publisher Correction: Genomic instability in mutant p53 cancer cells upon entotic engulfment (2018) (0)
- Abstract 6091: Evolutionary characterisation of lung adenocarcinoma pathological subtypes in TRACERx (2022) (0)
- 221 Multi-region whole exome sequencing reveals monoclonal nature of inferior vena cava tumour thrombus extension in clear cell renal cell carcinoma (2016) (0)
- Abstract B49: “Triple wild-type” co-mutational profile in early-stage KRAS-mutant lung cancer (2020) (0)
- Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer (2023) (0)
- Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality (2022) (0)
- Take lessons from cancer evolution to the clinic (2020) (0)
- Abstract IA23: Allele-specific HLA loss and immune escape in lung cancer evolution (2018) (0)
- Antigen Processing in a Human B Cell Line Down-Regulates MHC Expression and γ IFN- (2013) (0)
- 10: Intra-tumour heterogeneity in early-stage lung cancer inferred by multi-region sequencing (2014) (0)
- Quantification of tumour evolution and heterogeneity via Bayesian epiallele detection (2017) (0)
- Abstract IA07: UVB-induced tumor heterogeneity directs immune response in melanoma (2020) (0)
- 344 Cell-cycle Phase Specific Markers’ Expression in Breast Cancer (2012) (0)
- Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma (2018) (0)
- 7ODeciphering the intra-tumoural T cell receptor repertoire in patients with NSCLC within the lung TRACERx study (2017) (0)
- Intratumour Heterogeneity and tumour evolution in neuroendocrine cancers of the lung (2019) (0)
- deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution (2016) (0)
- 509 Immune checkpoint blockade boosts anti-tumour B cell responses in lung adenocarcinoma (2022) (0)
- Chromosomal instability determines taxane sensitivity - supplementary materials (2009) (0)
- Abstract IA12: Cancer evolution: Chromosomal instability and immune evasion (2022) (0)
- The use of next generation sequencing (NGS) to guide patient selection for phase 1 clinical trials (2016) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [ version 2 ; peer review : 2 approved ] (2021) (0)
- 1228P Integrated analysis of gene expression and chromosomal aberrations to determine the global patterns of DNA methylation heterogeneity in the TRACERx lung study (2020) (0)
- Abstract 827: A journey to deconvolute the multifaceted functions and context-dependency of cancer driver genes (2022) (0)
- Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. (2023) (0)
- Prognostic significance of pre-operative body composition in early stage NSCLC patients. (2020) (0)
- Abstract PO-018: Single cell whole genome sequencing reveals the dynamics of copy number instability at the earliest stages of cancer evolution (2020) (0)
- P03.30 Tumur mutations drive dysfunctional T cell differentiation in lung cancer (2020) (0)
- Lung cancer in the UK: addressing geographical inequality and late diagnosis. (2018) (0)
- Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses (2020) (0)
- Insights into the metastatic cascade through research autopsies. (2023) (0)
- Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine (2014) (0)
- Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (0)
- Abstract 3609: Defining extrinsic and intrinsic mechanisms of immune evasion in TRACERx using imaging mass cytometry (2022) (0)
- Can whole-body MRI replace ¹⁸F-fl uorodeoxyglucose PET/CT? (2014) (0)
- Abstract 2678: A clonal expression biomarker improves prognostic accuracy: TRACERx lung (2019) (0)
- Abstract 2908: Mesothelioma phylogeny reveal MTAP as a solitary clonal deletion, exposing vulnerability to the PRMT5 perturbagen, quinacrine (2019) (0)
- Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (0)
- Abstract 2197: Targeted cancer therapy induces APOBEC fueling the evolution of drug resistance (2022) (0)
- Using single cell data to validate the cellular origins of a clonal expression biomarker in lung cancer (2019) (0)
- Abstract 1211: Allele-specific copy-number based deconvolution of bulk tumour RNA sequencing data from the TRACERx study (2022) (0)
- Abstract LB504: Automated grading of growth patterns in lung adenocarcinoma-from TRACERx to LATTICe-A (2022) (0)
- University of Birmingham The National Lung Matrix Trial : translating the biology of stratification in advanced non-small-cell lung cancer (2015) (0)
- Paradoxical Relationship of Chromosomal Instability with Breast Cancer Outcome: Identification of a Good Prognostic ER Negative/HER2 Negative Breast Cancer Cohort with Extreme Chromosomal Instability. (2009) (0)
- A Functional Metagene Incorporating TTK Protein Kinase, Aurora Kinase B and Glucosylceramide Synthase Predicts Response to Treatment in Primary Breast Cancer (2009) (0)
- Molecular profiling of circulating tumour cells (CTCs) in non-small cell lung cancer within the TRACERx study of intratumoural heterogeneity and evolution (2016) (0)
- Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms (2013) (0)
- Abstract 2938: APOBEC3B and TKI resistance in EGFR mutant lung cancer (2021) (0)
- Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution (2014) (0)
- Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities (2021) (0)
- The Effects of Clonal Heterogeneity on Cancer Immunosurveillance (2023) (0)
- Association of the imbalance between early and late differentiated intra-tumor CD4 T cells with mutational burden in non-small cell lung cancer. (2019) (0)
- Simulations of 3D organoids suggest inhibitory neighbour-neighbour signalling as a possible growth mechanism in EGFR-L858R mutant alveolar type II cells (2023) (0)
- P405: INHIBITION OF CKS1-DEPENDENT PROTEOSTASIS REVEALS VULNERABILITIES IN LEUKAEMIC STEM CELLS WITH CONCOMITANT PROTECTION OF HEALTHY HAEMATOPOIETIC STEM CELLS (2022) (0)
- Abstract IA26: Multiplexed functional cancer genomics (2020) (0)
- Abstract LB013: Clinical validation of a targeted methylation-based multi-cancer early detection test (2021) (0)
- Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer. (2010) (0)
- Abstract 3105: Chromosome 18q encodes a chromosomal instability suppressor locus in colorectal cancer (2012) (0)
- 1437 POSTER Gene Expression Signature TOPFOX Reflecting Chromosomal Instability Refines Prediction of Prognosis in Grade 2 Breast Cancer (2011) (0)
- Abstract 3620: Investigating the role of altered replication timing during tumor evolution in lung and breast cancer (2022) (0)
- Better Molecular Profiling is Needed for Rational, Targeted Therapy in CRC (2014) (0)
- Abstract LB124: APOBEC3B fuels evolution of resistance during targeted cancer therapy (2021) (0)
- Stratification method based on RAS pathway oncogenic activity predicts outcome in lung adenocarcinoma (2020) (0)
- Abstract A040: Intra-epithelia cell dynamics shape evolutionary dynamics and selection of therapy resistant clones in lung cancer (2022) (0)
- Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (0)
- Publisher Correction: Genomic instability in mutant p53 cancer cells upon entotic engulfment (2018) (0)
- Immunogenomics of colorectal cancer response to immune checkpoint blockade: TCRseq (2020) (0)
- Abstract P6-07-15: The effect of taxanes in ER+ early breast cancer is likely to be mitigated by chromosomal instability. (2012) (0)
- Abstract 3584: Genomic analysis reveals a role for BCL9L in aneuploidy tolerance in colorectal cancer (2016) (0)
- 28P Identification of convergent gene repression mechanisms through integrative genomic and DNA methylation analysis in NSCLC (2022) (0)
- Reply to the letter to the editor 'Abandoning diesel because of health perspectives: are there reasonable alternatives?' by Vreugdenhil and Mannaerts. (2016) (0)
- Author Correction: The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis (2019) (0)
- 2MO Tracking immunoediting from early to late-stage lung cancer (2022) (0)
- Abstract 4603: Intratumor heterogeneity in clear cell renal cell carcinoma (ccRCC): Multi-region sequencing redefines the mutational landscape of ccRCCs. (2013) (0)
- Corrigendum: Replication stress links structural and numerical cancer chromosomal instability (2013) (0)
- 246 INVITED Functional Genomic Approaches to the Dissection of Cancer Drug Resistance Mechanisms (2011) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [version 1; peer review: 2 approved with reservations] (2021) (0)
- Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (0)
- Kaposi's Sarcoma Herpesvirus Encoded Cycun Disruption of Mammalian Cell Cycle Control Mechanisms (1999) (0)
- Abstract 3626: Genomic evolutionary patterns in matched pre-invasive and invasive lung disease in TRACERx (2022) (0)
- 703MO An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution (2020) (0)
- Abstract S12-02: Comprehensive meta-analysis of COVID-19 mortality rates for 22 cancer subtypes from the Reboot: COVID-Cancer Project, an interactive resource with aggregated data from 21,839 cancer patients (2021) (0)
- Abstract 6113: Spatially resolved biomarker detection on single cells in TRACERx using multiplex imaging (2022) (0)
- Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC). (2018) (0)
- Small and interfering (2005) (0)
- Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
- LBA36EVOLUTION OF THE GENOMIC LANDSCAPE IN NON-SMALL CELL LUNG CANCER (2014) (0)
- Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
- Abstract 1603: Genomic transcriptomic evolution in TRACERx lung cancer and metastasis (2022) (0)
- Chemotherapy and metastatic breast cancer (2011) (0)
- Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis (2020) (0)
- Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (0)
- Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (0)
- Mechanism informs precision: In vivo determinants of response to anti-CTLA-4 antibodies. (2018) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [version 1; peer review: awaiting peer review] (2021) (0)
- Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer (2023) (0)
- 1 Renal cell carcinoma 1 2 (2017) (0)
- DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer (2016) (0)
- Intratumoural (IT) evolutionary landscape of high-risk prostate cancer and outcome: The PROGENY (PROstate cancer GENomic heterogeneitY) study of genomic and immune parameters. (2020) (0)
- Circulating tumour DNA experience in patients with cancer of unknown primary. (2018) (0)
- [Simplified, low-cost gene expression profiling for the prediction of outcome in breast cancer based on routine histologic specimens]. (2013) (0)
- APOBEC3 as a driver of genetic intratumor heterogeneity (2022) (0)
- Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway (2022) (0)
- Abstract LB237: Functional characterisation of TRACERx reveals mechanisms of NSCLC evolution (2023) (0)
- Resolving genetic heterogeneity in cancer (2019) (0)
- Decision letter: A novel gene ZNF862 causes hereditary gingival fibromatosis (2021) (0)
- Abstract 5710: Identification of convergent gene repression mechanisms through integrative genomic and DNA methylation analysis in TRACERx (2022) (0)
- Abstract 4277: Measuring proliferation rates of distinct tumour clones using single-cell DNA sequencing (2023) (0)
- Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer. (2023) (0)
- Abstract 1926: Machine learning-enhanced image and spatial analytic pipelines for imaging mass cytometry applied to the TRACERx non-small cell lung cancer study (2022) (0)
- Abstract 1591: Convergence of antigenic diversity and Tex-cell stability fatally constrains immune surveillance in non-small cell lung cancer (TRACERx) and HIV-1 infection (Protocol C) (2022) (0)
- Detection of cancer signal for over 50 AJCC cancer types with a multi-cancer early-detection test. (2021) (0)
- Representative sequencing: Profiling extreme tumor diversity. (2018) (0)
- Body composition and lung cancer-associated cachexia in TRACERx (2023) (0)
- Author Correction: Resolving genetic heterogeneity in cancer (2019) (0)
- Reply to J.J. Tao et al. (2018) (0)
- The National Lung Matrix Trial of personalized therapy in lung cancer (2020) (0)
- Personalized Medicine and Imaging 89 Zr-trastuzumab and 89 Zr-bevacizumab PET to Evaluate the Effect of the HSP 90 Inhibitor NVP-AUY 922 in Metastatic Breast Cancer Patients (2014) (0)
- Pervasive chromosomal instability and karyotype order in tumour evolution (2020) (0)
- Neoantigen-directed immune escape in lung cancer evolution (2019) (0)
- Imaging in the management of metastatic breast cancer David MacVicar (2006) (0)
- Abstract PD3-1: Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT) (2015) (0)
- Abstract 67: Paralleled convergence of antigen load, disease progression and systemic T cell exhaustion in lung cancer and HIV-1 infection (2021) (0)
- Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice. (2012) (0)
- Abstract 2567: TRACERx: Intra-tumor subclonal driver mutation results in defective DNA damage response (DDR) and genome instability (2019) (0)
- Abstract 692: Patient-derived co-cultures of TRACERx lung cancer organoids and autologous T-cells reveal heterogeneity in immune evasion between cancer subclones (2022) (0)
- Neoantigen-directed immune escape in lung cancer evolution (2019) (0)
- Abstract LB064: B cells synergize with T cell regulation at immune hotspots in lung squamous cell carcinoma (2022) (0)
- Palaeoecology: What killed the big beasts? (2012) (0)
- Abstract 5055: Precise segmentation of growth patterns in TRACERx lung adenocarcinoma (2022) (0)
- Abstract 1349: Personalized circulating tumor DNA profiling in malignant pleural mesothelioma (2019) (0)
- Abstract 3043: Exploring the microbial landscape of NSCLC through TRACERx (2022) (0)
- Abstract 674: Tracking the transcriptome of lung cancer-associated fibroblasts within the TRACERx lung study from patient to culture models reveals phenotypic plasticity and instructive cues from cancer cells (2022) (0)
- FIRST RESULTS OF A‐PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY: PNFLBA‐16 (2017) (0)
- An HLA-G/SPAG9/STAT3 axis promotes brain metastases (2023) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [version 1; peer review: 1 approved with reservations] (2021) (0)
- Abstract 1390: Immunotherapy boosts B cell responses in lung adenocarcinoma (2022) (0)
- Abstract A011: Detection of disseminated tumor cells in advanced clear cell renal cell carcinoma through research autopsy (2023) (0)
- PO-342 Integrating copy number analysis and tumour DNA methylation profiling (2018) (0)
- Abstract 1394: Pervasive allele specific transcriptional repression of the class I and II HLA genes in TRACERx non-small cell lung cancer (2022) (0)
- 3094 – INHIBITION OF CKS1-DEPENDENT PROTEOSTASIS REVEALS VULNERABILITIES IN LEUKAEMIC STEM CELLS WITH CONCOMITANT PROTECTION OF HEALTHY HAEMATOPOIESIS (2022) (0)
- Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options. (2022) (0)
- Feeding Ecology of Maturing Sockeye Salmon (Oncorhynchus nerka) in Nearshore Waters of the Kodiak Archipelago (2001) (0)
- Abstract 3792: TRACERx: Mapping the evolution of metastases in non-small cell lung cancer (2022) (0)
- Cross-Stream Interactions: Segmentation of Lung Adenocarcinoma Growth Patterns (2022) (0)
- Clonal evolution in healthy and premalignant tissues: implications for early cancer interception strategies. (2023) (0)
- Abstract 2144: Holistic sampling of clonal dynamics using cfDNA in lung TRACERx (2022) (0)
- Abstract 5636: V-delta-1 T cells are resident in the human lung and associate with survival in patients with non-small cell lung cancer in the TRACERx Study (2022) (0)
- Chromosomal instability , aneuploidy , and cancer Samuel (2014) (0)
- Abstract 1699: SignaTree: A tool to identify evolutionary trajectories of the activity of mutational processes in TRACERx (2022) (0)
- Refphase: Multi-sample reference phasing reveals haplotype-specific copy number heterogeneity (2022) (0)
- Abstract 861: Modelling the role of EGFR mutation in the initiation of never-smoker lung cancer (2023) (0)
- Abstract LB153: Clinical relevance of spatial intermixing of growth patterns and immune infiltration in lung adenocarcinoma-from TRACERx to LATTICe-A (2022) (0)
- A comprehensive survey of the mutagenic impact of common cancer cytotoxics (2016) (0)
- Representative sequencing: Profiling extreme tumor diversity. (2018) (0)
- Abstract 6217: TP53 loss with whole genome doubling mediates heterogeneous intra-patient therapy response in EGFR-driven lung adenocarcinoma: A TRACERx study (2022) (0)
- Cell-free DNA (c.f.D.N.A) recapitulates genomic profile of renal cell carcinoma (R.C.C) and corresponds to disease progression and therapy response (2018) (0)
- Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care (2023) (0)
- Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality (2022) (0)
- Abstract 3137: Somatic structure variants as a biomarker to predict immune checkpoint inhibitor response by generating anti-tumour antigen (2023) (0)
- Next-generation detection of antigen-responsive T cells using DNA barcode-labeled MHC-I 1 multimers (2016) (0)
- Abstract LB-453: Phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC). A biomarker driven study using ultra deep genome sequencing technology (2012) (0)
- Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer (2012) (0)
- Modelled mortality benefits of multi-cancer early detection screening in England (2023) (0)
- Biomarker profiles and changes from baseline in trastuzumab (T) refractory HER2-positive inflammatory breast cancer (IBC) that predict decreases in tumor burden from lapatinib (L) monotherapy. (2010) (0)
- Contrasting the drivers of response to immunotherapy across solid tumour types: Results from analysis of > 1000 cases (2019) (0)
- Dropping the C word (2019) (0)
- Abstract 204: Notch2NL is a novel regulator of radiation sensitivity in non-small cell lung cancer and a positive regulator of MYC activity (2022) (0)
- Abstract LB258: Branching cancer evolution biases the detection of epistatic interactions between driver mutations (2021) (0)
- Circulating tumour cells as liquid biopsies in clinical studies: the example of TRACERx. (2018) (0)
- A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors (2013) (0)
- Abstract 643: Non-classical sources of tumour specific antigen in checkpoint inhibitor response (2022) (0)
- Cell-free circulating tumour DNA (ctDNA) in the management of patients (pts) with non-biopsiable (Bx) advanced non-small cell lung cancer (NSCLC). (2018) (0)
- Prediction of the prognosis of breast cancer in routine histologic specimens using a simplified, low-cost gene expression signature (2013) (0)
- Abstract 821: Dissecting the role of Stag2 in lung adenocarcinoma (2022) (0)
- Impact of risk factors on early cancer evolution (2023) (0)
- Angelika Amon (1967-2020). (2020) (0)
- Abstract 645: Heterogeneity of immunotherapy biomarkers in the TRACERx non-small cell lung cancer multi-region lung cancer cohort study (2022) (0)
- The role of NOTCH2NLB in NSCLC and resistance to ionising radiation (2020) (0)
- 114 Clonal mTOR pathway activation as a predictive biomarker for mTOR inhibitor therapy in clear cell renal cell carcinoma (2016) (0)
- Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (0)
- 11 The switch to invasiveness in lung adenocarcinoma (2016) (0)
- Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (0)
- Abstract IA15: Genetic and functional tumor heterogeneity (2013) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [version 2; peer review: 2 approved with reservations] (2021) (0)
- Abstract 1192: Establishment and characterization of a new patient-derived renal cell carcinoma xenograft panel (2014) (0)
- New Targets and Innovative Strategies in Cancer Treatment: one year of progress. 13-14 February 2004, Nice, France. (2004) (0)
- Chromosomal Instability, Aneuploidy, and Cancer The made this article openly available. Please share how this access benefits you. Your story matters (2014) (0)
- Abstract IA16: Cancer evolution, immune evasion and metastasis (2020) (0)
- Triple wild-type' co-mutational profile in early-stage KRAS-mutant lung cancer (2020) (0)
This paper list is powered by the following services:
Other Resources About Charles Swanton
What Schools Are Affiliated With Charles Swanton?
Charles Swanton is affiliated with the following schools:
